Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using ...
It uses electromagnetic waves to target tumors and is available to patients for whom first- and second-line treatments have ...
MCCLEAN, VA, UNITED STATES, December 16, 2024 /EINPresswire / -- Perthera, the leader in AI-driven Precision Oncology Decision Support, has unveile ...
Ensartinib has received FDA approval for the first-line treatment of ALK-positive locally advanced or metastatic non–small ...
From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.
Coherus BioSciences, Inc. ("Coherus,” NASDAQ: CHRS) today announced that an abstract highlighting final clinical and biomarker data from its Phase 2 clinical trial evaluating casdozokitug (casdozo), a ...
A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either ...
RemeGen’s Phase III trial of disitamab vedotin shows improved progression-free survival in advanced breast cancer patients ...
Ensartinib has received FDA approval for the first-line treatment of anaplastic lymphoma kinase (ALK)-positive locally ...
On the morning of2, 2024 (UTC-6), at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San Antonio Breast Cancer Symposium (SABCS), RemeGen Co. Ltd. ("RemeGen") (9995.HK, 688331.SH) ...
Title: Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug in combination with atezolizumab and bevacizumab in patients with unresectable, ...
MALMO, SWEDEN / ACCESSWIRE / December 17, 2024 / Ascelia Pharma (STO:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that two scientific abs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback